HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: Immunologic and virologic responses to zidovudine

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 17, Issue 3, 1998, Pages 203-208

  Rey, David ^a   Hughes, Michael ^b   Pi, Ju Tsung ^b   Winters, Mark ^a   Merigan, Thomas C ^a   Katzenstein, David A ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

Author keywords

Codon 215; HIV 1; Mutation; Plasma RNA; Response, immunologic; Response, virologic; Reverse transcriptase; Zidovudine

Indexed keywords

PHENYLALANINE; RNA DIRECTED DNA POLYMERASE; THREONINE; TYROSINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CODON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VIRUS MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0032031609     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199803010-00003     Document Type: Article

References (25)

1. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-4.
2. Boucher CAB, Tersmette M, Lange JMA, et al. Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 1990;336:585-90.
3. Montaner JSG, Singer J, Scheeler MT, et al. Clinical correlates of in-vitro HIV-1 resistance to zidovudine: results of the multicenter Canadian AZT trial. AIDS 1993;7:189-96.
4. Japour AS, Welles S, D'Aquilla RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 1995;171:1172-9.
5. Land S, McGavin C, Lucas R, Birch C. Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during and after therapy. J Infect Dis 1992;166:1139-42.
6. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimcrob Agents Chemother 1993;37:1207-13.
7. Larder BA, Kellam P, Kemp SD. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991;5:137-44.
8. Richman DD, Guatelli JC, Grimes J, Tsiatis A, Gingeras T. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction. J Infect Dis 1991;164:1075-81.
9. Larder BA. Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-8.
10. Kellam P, Boucher CAB, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high level resistance to zidovudine. Proc Natl Acad Sci USA 1992;89:1934-8.
11. Boucher CAB, O'Sullivan E, Mulder JW, et al. Ordered appearance of mutations associated with drug resistance in human immunodeficiency virus-positive subjects. J Infect Dis 1992;165: 105-10.
12. Najera I, Richman DD, Olivares I, et al. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1994;10:1479-88.
13. Najera I, Holguin A, Quinones-Mateu ME, Munoz-Fernandez MA, Najera R, Lopez-Galindez C, Domingo E. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995;69:23-31.
14. Mohri H, Singh MK, Ching WTW, Ho DD. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc Natl Acad Sci USA 1993;90:25-9.
15. Veenstra J, Schuurman R, Cornelissen M, et al. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: charcteristics and natural history of the virus. Clin Infect Dis 1995;21:556-60.
16. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Aguininiga E, Halpern J, Merigan TC. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. J Acquir Immune Defic Syndr 1994;7:832-8.
17. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993;167:526-32.
18. Calderon EJ, Torres Y, Medrano FJ, et al. Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients. Eur J Clin Microbiol Infect Dis 1995;14:512-9.
19. Tudor-Williams G, St. Clair MH, McKinney RE, et al. HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 1992;339:15-9.
20. Ogino MT, Dankner WM, Spector SA. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus. J Pediatr 1993;123:1-8.
21. Nielsen K, Wei LS, Sim MS, et al. Correlation of clinical progression in human immunodeficiency virus-infected children with in vitro zidovudine resistance measured by a direct quantitative peripheral blood lymphocyte assay. J Infect Dis 1995;172:359-64.
22. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy: AIDS clinical trials group protocol 116B/117 team and the virology committee resistance working group. Ann Intern Med 1995;122:401-8.
23. Katzenstein DA, Hammer SM, Hughes MD, et al. Treatment of human immunodeficiency virus infection with nucleoside analog reverse transcriptase inhibitors: relationship of virologic and immunologic markers with outcome in ACTG 175. N Engl J Med 1996;335:1091-8.
24. Fiscus S, DeGruttola V, Gupta P, et al. Human immunodeficiency virus type-1 quantitative cell microculture as a measure of antiviral efficacy in a multi-center clinical trial. J Infect Dis 1995;171: 1305-11.
25. Larder BA, Kellam P, Kemp SD. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991;5:137-44.